[Digitoxin blood picture and renal elimination in long-term therapy with aluminum-magnesium hydroxide gel].
In ten patients in heart failure for which they were on long-term administration of digitoxin, the influence of aluminium-magnesium hydroxide gel (Maaloxan) on steady-state digitoxin plasma concentration and renal glycoside excretion was studied. Compared with control values before antacid medication (13.6 +/- 4.4 ng/ml), the administration of 20 ml aluminium-magnesium hydroxide gel three or four times daily for several weeks caused no significant change in digitoxin plasma levels (15.1 +/- 4.9 ng/ml). Daily renal glycoside excretion, as a further measure of bioavailability of digitoxin, was also unchanged by the antacid. Therapeutic plasma concentrations of digitoxin are not influenced by antacids which contain aluminium-magnesium hydroxide, at least not if the antacid is taken 1-2 hours after the digitoxin dose.
D000368:Aged; D000536:Aluminum Hydroxide / Q000627:therapeutic use*; D004074:Digitoxin / Q000008:administration & dosage / Q000378:metabolism*; D004338:Drug Combinations / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D006027:Glycosides / Q000032:analysis; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D008274:Magnesium / Q000627:therapeutic use*; D008276:Magnesium Hydroxide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D004338:Drug Combinations; D006027:Glycosides; C013591:aluminum hydroxide, magnesium hydroxide, drug combination; D000536:Aluminum Hydroxide; D004074:Digitoxin; D008274:Magnesium; D008276:Magnesium Hydroxide
Plasmaspiegel und renale Elimination von Digitoxin bei Langzeittherapie mit Aluminium-Magnesium-Hydroxid-Gel.